Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 23 (Search time: 0.009 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2017CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patientsBarratt, D.; Cox, H.; Menelaou, A.; Yeung, D.; White, D.; Hughes, T.; Somogyi, A.
2013BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistanceParker, W.; Yeoman, A.; Jamison, B.; Yeung, D.; Scott, H.; Hughes, T.; Branford, S.
2013PCR-mediated recombination can lead to artificial chimera formation, which may pose as BCR-ABL1 compound mutationsParker, W.; Phillis, S.; Yeung, D.; Hughes, T.; Scott, H.; Branford, S.; 55th American Society of Hematology Annual Meeting and Exhibition (07 Dec 2013 - 10 Dec 2013 : New Orleans, Louisiana)
2014The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatmentBranford, S.; Yeung, D.; Ross, D.; Parker, W.; Braley, J.; Seymour, J.; Hughes, T.; 56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)
2014Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepointBranford, S.; Ross, D.; Yeung, D.; Braley, J.; Hughes, T.; 56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)
2018Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expressionMcClure, B.; Heatley, S.; Kok, C.; Sadras, T.; An, J.; Hughes, T.; Lock, R.; Yeung, D.; Sutton, R.; White, D.
2017A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOHSadras, T.; Heatley, S.; Kok, C.; McClure, B.; Yeung, D.; Hughes, T.; Sutton, R.; Ziegler, D.; White, D.
2017Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesionsSadras, T.; Heatley, S.; Kok, C.; Dang, P.; Galbraith, K.; McClure, B.; Muskovic, W.; Venn, N.; Moore, S.; Osborn, M.; Revesz, T.; Moore, A.; Hughes, T.; Yeung, D.; Sutton, R.; White, D.
2010Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trialYeung, D.; Osborn, M.; White, D.; Branford, S.; Haswell, L.; Slader, C.; Issa, S.; Hiwase, D.; Hertzberg, M.; Schwarer, A.; Filshie, R.; Arthur, C.; Kwan, Y.; Forsyth, C.; Ross, D.; Mills, A.; Grigg, A.; Hughes, T.; Annual Meeting of the American Society of Hematology (52nd : 2010 : Orlando, Fl.)
2014High plasma levels of TGF-α and IL-6 at diagnosis predict early molecular response failure and transformation in CMLNievergall, E.; Reynolds, J.; Kok, C.; Watkins, D.; Biondo, M.; Busfield, S.; Vairo, G.; Yeung, D.; Lopez, A.; Hiwase, D.; White, D.; Hughes, T.; 56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)